Cargando…

Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients

To compare the value of cytokeratin fragment 21-1 (CYFRA 21-1) concentration in the fine-needle biopsy aspirates (fine needle aspirate [FNA] CYFRA 21-1) with cytopathology of fine-needle aspiration biopsy (FNA cytology) and to assess whether CYFRA 21-1 concentrations from ultrasound-guided fine-need...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Ji Soo, Han, Kyung Hwa, Kim, Eun-Kyung, Moon, Hee Jung, Yoon, Jung Hyun, Kim, Min Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602573/
https://www.ncbi.nlm.nih.gov/pubmed/25984666
http://dx.doi.org/10.1097/MD.0000000000000811
_version_ 1782394748710944768
author Choi, Ji Soo
Han, Kyung Hwa
Kim, Eun-Kyung
Moon, Hee Jung
Yoon, Jung Hyun
Kim, Min Jung
author_facet Choi, Ji Soo
Han, Kyung Hwa
Kim, Eun-Kyung
Moon, Hee Jung
Yoon, Jung Hyun
Kim, Min Jung
author_sort Choi, Ji Soo
collection PubMed
description To compare the value of cytokeratin fragment 21-1 (CYFRA 21-1) concentration in the fine-needle biopsy aspirates (fine needle aspirate [FNA] CYFRA 21-1) with cytopathology of fine-needle aspiration biopsy (FNA cytology) and to assess whether CYFRA 21-1 concentrations from ultrasound-guided fine-needle aspiration biopsy (US-FNAB) specimens (FNA CYFRA 21-1) is not inferior to FNA cytology in the diagnosis of axillary lymph node (ALN) metastasis of breast cancer patients. This study received institutional review board approval, and written informed consent was obtained from all patients. US-FNAB was performed in 373 ALNs from 358 patients with invasive breast cancer. Concentrations of CYFRA 21-1 were measured from washouts of the syringe used during US-FNAB (FNA CYFRA 21-1), and ALN metastasis was determined using a cutoff value of 1.93 ng/mL. FNA cytology, intraoperative sentinel lymph node biopsy, and surgical pathology results were reviewed and analyzed. The noninferiority margin for the difference in accuracies between FNA cytology and FNA CYFRA 21-1 was set as 5%. Among 373 ALNs, 136 (36.5%) were benign, and 237 (63.5%) were metastatic. The mean FNA CYFRA 21-1 was significantly higher in metastatic ALNs compared to that in benign ALNs (P = 0.001). For the diagnosis of ALN metastasis, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FNA CYFRA 21-1 (cutoff value 1.93 ng/mL) were not significantly different from those of FNA cytology (P > 0.05). FNA CYFRA 21-1 reached statistical noninferiority to FNA cytology in terms of diagnostic accuracy for ALN metastasis. Of the 20 ALNs (8 metastasis, 12 benign) that showed insufficient results on FNA cytology, FNA CYFRA 21-1 accurately diagnosed 15 ALNs (4 metastasis, 11 benign). The diagnostic performance of FNA CYFRA 21-1 is comparable with that of FNA cytology for breast cancer ALN metastasis. Our results indicate that FNA CYFRA 21-1, using an US-FNAB specimen, can be a useful method equal to FNA cytology in terms of diagnostic accuracy.
format Online
Article
Text
id pubmed-4602573
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46025732015-10-27 Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients Choi, Ji Soo Han, Kyung Hwa Kim, Eun-Kyung Moon, Hee Jung Yoon, Jung Hyun Kim, Min Jung Medicine (Baltimore) 6800 To compare the value of cytokeratin fragment 21-1 (CYFRA 21-1) concentration in the fine-needle biopsy aspirates (fine needle aspirate [FNA] CYFRA 21-1) with cytopathology of fine-needle aspiration biopsy (FNA cytology) and to assess whether CYFRA 21-1 concentrations from ultrasound-guided fine-needle aspiration biopsy (US-FNAB) specimens (FNA CYFRA 21-1) is not inferior to FNA cytology in the diagnosis of axillary lymph node (ALN) metastasis of breast cancer patients. This study received institutional review board approval, and written informed consent was obtained from all patients. US-FNAB was performed in 373 ALNs from 358 patients with invasive breast cancer. Concentrations of CYFRA 21-1 were measured from washouts of the syringe used during US-FNAB (FNA CYFRA 21-1), and ALN metastasis was determined using a cutoff value of 1.93 ng/mL. FNA cytology, intraoperative sentinel lymph node biopsy, and surgical pathology results were reviewed and analyzed. The noninferiority margin for the difference in accuracies between FNA cytology and FNA CYFRA 21-1 was set as 5%. Among 373 ALNs, 136 (36.5%) were benign, and 237 (63.5%) were metastatic. The mean FNA CYFRA 21-1 was significantly higher in metastatic ALNs compared to that in benign ALNs (P = 0.001). For the diagnosis of ALN metastasis, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FNA CYFRA 21-1 (cutoff value 1.93 ng/mL) were not significantly different from those of FNA cytology (P > 0.05). FNA CYFRA 21-1 reached statistical noninferiority to FNA cytology in terms of diagnostic accuracy for ALN metastasis. Of the 20 ALNs (8 metastasis, 12 benign) that showed insufficient results on FNA cytology, FNA CYFRA 21-1 accurately diagnosed 15 ALNs (4 metastasis, 11 benign). The diagnostic performance of FNA CYFRA 21-1 is comparable with that of FNA cytology for breast cancer ALN metastasis. Our results indicate that FNA CYFRA 21-1, using an US-FNAB specimen, can be a useful method equal to FNA cytology in terms of diagnostic accuracy. Wolters Kluwer Health 2015-05-21 /pmc/articles/PMC4602573/ /pubmed/25984666 http://dx.doi.org/10.1097/MD.0000000000000811 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial License, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be used commercially. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 6800
Choi, Ji Soo
Han, Kyung Hwa
Kim, Eun-Kyung
Moon, Hee Jung
Yoon, Jung Hyun
Kim, Min Jung
Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients
title Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients
title_full Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients
title_fullStr Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients
title_full_unstemmed Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients
title_short Fine-Needle Aspirate CYFRA 21-1, an Innovative New Marker for Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer Patients
title_sort fine-needle aspirate cyfra 21-1, an innovative new marker for diagnosis of axillary lymph node metastasis in breast cancer patients
topic 6800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602573/
https://www.ncbi.nlm.nih.gov/pubmed/25984666
http://dx.doi.org/10.1097/MD.0000000000000811
work_keys_str_mv AT choijisoo fineneedleaspiratecyfra211aninnovativenewmarkerfordiagnosisofaxillarylymphnodemetastasisinbreastcancerpatients
AT hankyunghwa fineneedleaspiratecyfra211aninnovativenewmarkerfordiagnosisofaxillarylymphnodemetastasisinbreastcancerpatients
AT kimeunkyung fineneedleaspiratecyfra211aninnovativenewmarkerfordiagnosisofaxillarylymphnodemetastasisinbreastcancerpatients
AT moonheejung fineneedleaspiratecyfra211aninnovativenewmarkerfordiagnosisofaxillarylymphnodemetastasisinbreastcancerpatients
AT yoonjunghyun fineneedleaspiratecyfra211aninnovativenewmarkerfordiagnosisofaxillarylymphnodemetastasisinbreastcancerpatients
AT kimminjung fineneedleaspiratecyfra211aninnovativenewmarkerfordiagnosisofaxillarylymphnodemetastasisinbreastcancerpatients